Jonatan Freilich1, Ali Manouchehrinia2, Mark Trusheim3, Lynn G Baird4, Sophie Desbiens4, Ernst Berndt5, Jan Hillert2. 1. Department of Management Engineering, Technical University of Denmark, Kongens Lyngby, Denmark/Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA. 2. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 3. Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA/Center of Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA, USA. 4. Center of Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA, USA. 5. Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA.
Abstract
BACKGROUND: Previous research characterizing factors influencing multiple sclerosis (MS) disease progression has typically been based on time to disease milestones (Kaplan-Meier, Cox hazard regression, etc.). A limitation of these methods is the handling of the often large groups of patients not reaching the milestone. OBJECTIVE: To characterize clinical factors influencing MS disease progression as annual transitions from each Expanded Disability Status Scale (EDSS). METHOD: The annual progression of 11,964 patients from the Swedish MS Registry was analysed with 10 multinomial logistic regressions, that is, one for transition from each full EDSS with explanatory variables age, sex, age at onset, time in current EDSS, highest prior EDSS, MS course and treatment. RESULTS: All factors (except sex) investigated had statistically significant impacts on transitions from at least one EDSS. However, significance and size of the effect are dependent on the EDSS state of the patient. Greater age, longer time in a state, highest prior EDSS, having progressive MS and treatment had significant impacts, whereas age at onset had minor impact. CONCLUSION: Our study confirms that established factors associated with MS disease worsening in time to disease milestones also have impacts on annual progression. This approach adds granularity to what EDSS these factors have an influence.
BACKGROUND: Previous research characterizing factors influencing multiple sclerosis (MS) disease progression has typically been based on time to disease milestones (Kaplan-Meier, Cox hazard regression, etc.). A limitation of these methods is the handling of the often large groups of patients not reaching the milestone. OBJECTIVE: To characterize clinical factors influencing MS disease progression as annual transitions from each Expanded Disability Status Scale (EDSS). METHOD: The annual progression of 11,964 patients from the Swedish MS Registry was analysed with 10 multinomial logistic regressions, that is, one for transition from each full EDSS with explanatory variables age, sex, age at onset, time in current EDSS, highest prior EDSS, MS course and treatment. RESULTS: All factors (except sex) investigated had statistically significant impacts on transitions from at least one EDSS. However, significance and size of the effect are dependent on the EDSS state of the patient. Greater age, longer time in a state, highest prior EDSS, having progressive MS and treatment had significant impacts, whereas age at onset had minor impact. CONCLUSION: Our study confirms that established factors associated with MS disease worsening in time to disease milestones also have impacts on annual progression. This approach adds granularity to what EDSS these factors have an influence.
Authors: Kristen M Krysko; Roland G Henry; Bruce A C Cree; Jue Lin; Stacy Caillier; Adam Santaniello; Chao Zhao; Refujia Gomez; Carolyn Bevan; Dana L Smith; William Stern; Gina Kirkish; Stephen L Hauser; Jorge R Oksenberg; Jennifer S Graves Journal: Ann Neurol Date: 2019-10-02 Impact factor: 10.422
Authors: Michelle Zuo; Naomi M Fettig; Louis-Philippe Bernier; Elisabeth Pössnecker; Shoshana Spring; Annie Pu; Xianjie I Ma; Dennis Sw Lee; Lesley A Ward; Anshu Sharma; Jens Kuhle; John G Sled; Anne-Katrin Pröbstel; Brian A MacVicar; Lisa C Osborne; Jennifer L Gommerman; Valeria Ramaglia Journal: JCI Insight Date: 2022-06-22